Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
15.9M
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
284K
-
Shares change
-
+108K
-
Total reported value, excl. options
-
$326K
-
Value change
-
+$120K
-
Number of buys
-
8
-
Number of sells
-
-6
-
Price
-
$1.15
Significant Holders of ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) as of Q2 2024
17 filings reported holding ADIL - ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share as of Q2 2024.
ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 284K shares
of 15.9M outstanding shares and own 1.78% of the company stock.
Largest 10 shareholders include UBS Group AG (83.6K shares), Manchester Capital Management LLC (48.1K shares), RENAISSANCE TECHNOLOGIES LLC (34.3K shares), HRT FINANCIAL LP (29.2K shares), BlackRock Inc. (27.8K shares), GEODE CAPITAL MANAGEMENT, LLC (25.9K shares), CITADEL ADVISORS LLC (24.7K shares), Tower Research Capital LLC (TRC) (5.63K shares), 1620 INVESTMENT ADVISORS, INC. (3.6K shares), and BANK OF AMERICA CORP /DE/ (689 shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.